Ziad Berri, MD
Internal Medicine · Dearborn, MINPI 1881786770
Payments from drug & device makers
Across 1,242 payments — averaging $24.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$3K
- AstraZeneca$3K
- Amgen$3K
- GSK$2K
- Cequr Corporation$2K
- AbbVie$2K
- plus $16K from 42 others
What the payments were for
- Speaking & faculty fees$2001%
- Food & beverage$30,60799%
- Education$560%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CeQur Simplicity$1,829
- Kerendia$881
- REXULTI$614
- Repatha$510
- AIRSUPRA$507
- JARDIANCE$495
- VRAYLAR$490
- INJECTAFER$482
- Ozempic$375
- AREXVY$374
- AIMOVIG$362
- BREZTRI$357
- TRELEGY ELLIPTA$356
- Saxenda$348
- CAPLYTA$255
- Wegovy$250
- IBSRELA$247
- SOLIQUA 100/33$244
- ELIQUIS$243
- FARXIGA$237
How this compares
$30,863 in reported general payments places this provider in the 95th percentile of 4,567 internal medicine providers in Michigan.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 377 | $289,926 |
| FarxigaDapagliflozin Propanediol | 244 | $184,860 |
| OzempicSemaglutide | 169 | $182,637 |
| EliquisApixaban | 185 | $138,096 |
| LinzessLinaclotide | 199 | $122,975 |
| MounjaroTirzepatide | 89 | $108,348 |
| TradjentaLinagliptin | 156 | $97,175 |
| JanuviaSitagliptin Phosphate | 118 | $81,395 |
| MyrbetriqMirabegron | 153 | $78,838 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 100 | $73,279 |
| RybelsusSemaglutide | 48 | $68,229 |
| EntrestoSacubitril/Valsartan | 55 | $50,268 |
| XareltoRivaroxaban | 63 | $49,073 |
| TrulicityDulaglutide | 41 | $47,558 |
| JanumetSitagliptin Phos/Metformin Hcl | 47 | $40,769 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance, Tradjenta, Trijardy Xr, Glyxambi | $1,522 | $419,962579 claims |
| Novo NordiskOzempic, Rybelsus | $3,312 | $250,867217 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Brilinta | $3,225 | $212,050295 claims |
| MerckJanuvia, Janumet, Janumet Xr | $661 | $156,854215 claims |
| Lilly USA, LLCMounjaro, Trulicity | $1,404 | $155,907130 claims |
| PfizerEliquis | $1,336 | $138,096185 claims |
| AbbVieLinzess, Restasis | $1,668 | $134,405217 claims |
| GSKTrelegy Ellipta, Anoro Ellipta | $1,983 | $95,316143 claims |
| Astellas Pharma US IncMyrbetriq | $808 | $78,838153 claims |
| NovartisEntresto | $268 | $50,26855 claims |
| Johnson & JohnsonXarelto | $638 | $49,07363 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $712 | $35,70635 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 4,567 internal medicine providers in Michigan.
Other internal medicine in Dearborn
- Abdulhassan SaadDearborn$11.5M
- Ali HazimehDearborn$1.5M
- Ulka VaishampayanAnn Arbor$33.7M
- Jeffrey PottsBay City$14.7M
- Neil FraserTroy$14.3M
- Leslie PelkeyGrand Rapids$8.5M
- Jay SandbergTroy$8.3M
- Ding WangDetroit$6.8M
- Dipenkumar ModiDetroit$4.1M
- Ahmed ArifFlint$4.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.